
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. demonstrates a positive financial outlook, evidenced by a 43% increase in its revenue for the third quarter of 2025, surpassing consensus estimates, alongside a management-guided raise in gross margin expectations to 76-77% for the year. The company's strategic focus on enhancing light adjustable lens (LAL) volumes, coupled with initiatives aimed at expanding the installed base of light delivery devices (LDD), indicates potential for further growth and operational efficiency. Additionally, RxSight's prudent management of operating expenses, alongside an anticipated improvement in margins, reinforces its position for sustainable profitability in the evolving medical technology landscape.
Bears say
RxSight Inc. has reported a decline in monthly utilization of its Light Adjustable Lenses (LALs), dropping to 8.0 units per Light Delivery Device (LDD) in Q3 2025, a decrease from both the previous quarter and the same quarter last year. The company's revenue for the most recent period was $30.3 million, representing a 14% year-over-year decline, with guidance for FY2026 revenue projected at $120-135 million, underperforming compared to existing estimates. Additionally, although operating expenses saw a slight reduction, gross margins are expected to be adversely affected by higher-cost inventory starting in Q2 2026, further contributing to a negative financial outlook.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares